CL2014000590A1 - Anticuerpo o fragmento de union a antigeno del mismo que se une a pcsk9 humana; composicion farmaceutica que lo comprende; y su uso para tratar hiperlipidemia o hipercolesterolemia. - Google Patents

Anticuerpo o fragmento de union a antigeno del mismo que se une a pcsk9 humana; composicion farmaceutica que lo comprende; y su uso para tratar hiperlipidemia o hipercolesterolemia.

Info

Publication number: CL2014000590A1
Authority: CL; Chile
Prior art keywords: hypercholesterolemia; binds; antibody; pharmaceutical composition; antigen binding
Prior art date: 2011-09-16

Application number

CL2014000590A

Other languages

English (en)

Inventor

Julian Davies

Barrett Allan

Ryan James Darling

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-09-16

Filing date

2014-03-12

Publication date

2014-10-17

2014-03-12 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2014-10-17 Publication of CL2014000590A1 publication Critical patent/CL2014000590A1/es

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Hematology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Obesity (AREA)
General Chemical & Material Sciences (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CL2014000590A 2011-09-16 2014-03-12 Anticuerpo o fragmento de union a antigeno del mismo que se une a pcsk9 humana; composicion farmaceutica que lo comprende; y su uso para tratar hiperlipidemia o hipercolesterolemia. CL2014000590A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201161535625P	2011-09-16	2011-09-16

Publications (1)

Publication Number	Publication Date
CL2014000590A1 true CL2014000590A1 (es)	2014-10-17

Family

ID=46881177

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2014000590A CL2014000590A1 (es)	2011-09-16	2014-03-12	Anticuerpo o fragmento de union a antigeno del mismo que se une a pcsk9 humana; composicion farmaceutica que lo comprende; y su uso para tratar hiperlipidemia o hipercolesterolemia.

Country Status (29)

Country	Link
US (1)	US8530414B2 (es)
EP (1)	EP2756003A1 (es)
JP (1)	JP6013487B2 (es)
KR (1)	KR101607783B1 (es)
CN (1)	CN103781802B (es)
AP (1)	AP2014007499A0 (es)
AR (1)	AR087715A1 (es)
AU (1)	AU2012308786B2 (es)
BR (1)	BR112014005799A2 (es)
CA (1)	CA2845706C (es)
CL (1)	CL2014000590A1 (es)
CO (1)	CO6910164A2 (es)
CR (1)	CR20140087A (es)
DO (1)	DOP2014000041A (es)
EA (1)	EA024430B1 (es)
EC (1)	ECSP14013242A (es)
GT (1)	GT201400049A (es)
IL (1)	IL231282A0 (es)
MA (1)	MA35433B1 (es)
MX (1)	MX347475B (es)
MY (1)	MY168961A (es)
PE (1)	PE20141147A1 (es)
PH (1)	PH12014500576A1 (es)
SG (1)	SG2014014187A (es)
TN (1)	TN2014000094A1 (es)
TW (1)	TWI586687B (es)
UA (1)	UA114604C2 (es)
WO (1)	WO2013039958A1 (es)
ZA (1)	ZA201401267B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11904017B2 (en)	2015-08-18	2024-02-20	Regeneron Pharmaceuticals, Inc.	Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JOP20080381B1 (ar)	2007-08-23	2023-03-28	Amgen Inc	بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
JO3672B1 (ar)	2008-12-15	2020-08-27	Regeneron Pharma	أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130064834A1 (en)	2008-12-15	2013-03-14	Regeneron Pharmaceuticals, Inc.	Methods for treating hypercholesterolemia using antibodies to pcsk9
PL3395836T3 (pl)	2011-01-28	2021-12-13	Sanofi Biotechnology	Ludzkie przeciwciała przeciwko pcsk9 do zastosowania w sposobach leczenia konkretnych grup osobników
JOP20200043A1 (ar)	2011-05-10	2017-06-16	Amgen Inc	طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
AR087305A1 (es)	2011-07-28	2014-03-12	Regeneron Pharma	Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
ES2992345T3 (es)	2011-09-16	2024-12-11	Regeneron Pharma	Métodos para reducir los niveles de lipoproteína(a) mediante la administración de un inhibidor de la proproteína convertasa subtilisina kexina-9 (PCSK9)
US9255154B2 (en)	2012-05-08	2016-02-09	Alderbio Holdings, Llc	Anti-PCSK9 antibodies and use thereof
US10058630B2 (en) *	2012-10-22	2018-08-28	Concievalve, Llc	Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis
US10111953B2 (en)	2013-05-30	2018-10-30	Regeneron Pharmaceuticals, Inc.	Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
EP2810955A1 (en)	2013-06-07	2014-12-10	Sanofi	Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
EP2862877A1 (en)	2013-10-18	2015-04-22	Sanofi	Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
TW202021614A (zh)	2013-06-07	2020-06-16	法商賽諾菲生物技術公司	藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法
JP6267792B2 (ja) *	2013-06-28	2018-01-24	アムジエン・インコーポレーテツド	ホモ接合性家族性高コレステロール血症の治療方法
MX2016006226A (es)	2013-11-12	2016-09-07	Sanofi Biotechnology	Regimenes de dosificacion para uso con inhibidores de pcsk9.
US8980273B1 (en)	2014-07-15	2015-03-17	Kymab Limited	Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8945560B1 (en)	2014-07-15	2015-02-03	Kymab Limited	Method of treating rheumatoid arthritis using antibody to IL6R
US9045548B1 (en)	2014-07-15	2015-06-02	Kymab Limited	Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9051378B1 (en)	2014-07-15	2015-06-09	Kymab Limited	Targeting rare human PCSK9 variants for cholesterol treatment
US9017678B1 (en)	2014-07-15	2015-04-28	Kymab Limited	Method of treating rheumatoid arthritis using antibody to IL6R
US9023359B1 (en)	2014-07-15	2015-05-05	Kymab Limited	Targeting rare human PCSK9 variants for cholesterol treatment
DE202014010499U1 (de)	2013-12-17	2015-10-20	Kymab Limited	Targeting von humaner PCSK9 zur Cholesterinbehandlung
US9914769B2 (en)	2014-07-15	2018-03-13	Kymab Limited	Precision medicine for cholesterol treatment
US8883157B1 (en)	2013-12-17	2014-11-11	Kymab Limited	Targeting rare human PCSK9 variants for cholesterol treatment
US8986694B1 (en)	2014-07-15	2015-03-24	Kymab Limited	Targeting human nav1.7 variants for treatment of pain
US8992927B1 (en)	2014-07-15	2015-03-31	Kymab Limited	Targeting human NAV1.7 variants for treatment of pain
US9045545B1 (en)	2014-07-15	2015-06-02	Kymab Limited	Precision medicine by targeting PD-L1 variants for treatment of cancer
US8986691B1 (en)	2014-07-15	2015-03-24	Kymab Limited	Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9067998B1 (en)	2014-07-15	2015-06-30	Kymab Limited	Targeting PD-1 variants for treatment of cancer
US9034332B1 (en)	2014-07-15	2015-05-19	Kymab Limited	Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
GB201403775D0 (en)	2014-03-04	2014-04-16	Kymab Ltd	Antibodies, uses & methods
CN105085684B (zh) *	2014-05-14	2020-04-17	上海亨臻实业有限公司	Pcsk9靶向重组疫苗设计及其应用
US9150660B1 (en)	2014-07-15	2015-10-06	Kymab Limited	Precision Medicine by targeting human NAV1.8 variants for treatment of pain
DE202015009002U1 (de)	2014-07-15	2016-08-18	Kymab Limited	Targeting von humaner PCSK9 zur Cholesterinbehandlung
EP4328245A3 (en)	2014-07-15	2024-06-05	Kymab Ltd.	Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
US9139648B1 (en)	2014-07-15	2015-09-22	Kymab Limited	Precision medicine by targeting human NAV1.9 variants for treatment of pain
EP2975059A1 (en)	2014-07-15	2016-01-20	Kymab Limited	Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
PL3169353T3 (pl)	2014-07-16	2020-06-01	Sanofi Biotechnology	SPOSOBY LECZENIA PACJENTÓW Z HETEROZYGOTYCZNĄ HIPERCHOLESTEROLEMIĄ RODZINNĄ (heFH)
WO2016023916A1 (en)	2014-08-12	2016-02-18	Kymab Limited	Treatment of disease using ligand binding to targets of interest
WO2016071701A1 (en)	2014-11-07	2016-05-12	Kymab Limited	Treatment of disease using ligand binding to targets of interest
EP3973958A3 (en)	2015-03-20	2022-06-22	Aarhus Universitet	Inhibitors of pcsk9 for treatment of lipoprotein metabolism disorders
US11052175B2 (en)	2015-08-19	2021-07-06	Musculoskeletal Transplant Foundation	Cartilage-derived implants and methods of making and using same
CN106810609A (zh) *	2015-11-27	2017-06-09	苏州君盟生物医药科技有限公司	抗pcsk9抗体及其应用
JP7032662B2 (ja) *	2015-12-31	2022-03-09	ジエンスヘンルイメデイシンカンパニーリミテッド	Ｐｃｓｋ９抗体、その抗原結合フラグメント及び医薬用途
CN107531795B (zh) *	2016-01-05	2021-01-19	江苏恒瑞医药股份有限公司	Pcsk9抗体、其抗原结合片段及其医药用途
KR102379464B1 (ko)	2016-06-20	2022-03-29	키맵 리미티드	항-pd-l1 항체
WO2018054240A1 (en) *	2016-09-20	2018-03-29	Wuxi Biologics (Shanghai) Co. Ltd.	Novel anti-pcsk9 antibodies
EP3534947A1 (en)	2016-11-03	2019-09-11	Kymab Limited	Antibodies, combinations comprising antibodies, biomarkers, uses & methods
JOP20190112A1 (ar)	2016-11-14	2019-05-14	Amgen Inc	علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي
CN108424457B (zh) *	2017-02-13	2021-06-01	成都金洛克锶生物技术有限公司	针对pcsk9抗体与检测试剂盒的制备及其用途
BR112019020148A2 (pt)	2017-04-13	2020-05-05	Cadila Healthcare Limited	peptídeo
SG11202107614PA (en)	2019-01-18	2021-08-30	Astrazeneca Ab	Pcsk9 inhibitors and methods of use thereof
EP3969620B1 (en)	2019-05-17	2025-06-25	Regeneron Pharmaceuticals, Inc.	Genome-based methods for reducing cardiovascular risk
CN114369164A (zh) *	2020-10-15	2022-04-19	苏州君盟生物医药科技有限公司	抗pcsk9单克隆抗体的生产工艺

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU1099601A (en)	1999-10-22	2001-05-08	Millennium Pharmaceuticals, Inc.	Nucleic acid molecules derived from rat brain and programmed cell death models
EP1309614A2 (en)	2000-08-11	2003-05-14	Eli Lilly And Company	Novel secreted proteins and their uses
US7572618B2 (en)	2006-06-30	2009-08-11	Bristol-Myers Squibb Company	Polynucleotides encoding novel PCSK9 variants
WO2008133647A2 (en)	2006-11-07	2008-11-06	Merck & Co., Inc.	Antagonists of pcsk9
US20100040611A1 (en)	2006-11-07	2010-02-18	Sparrow Carl P	Antagonists of pcsk9
CA2667894A1 (en)	2006-11-07	2008-05-15	Merck & Co., Inc.	Antagonists of pcsk9
WO2008057458A2 (en)	2006-11-07	2008-05-15	Merck & Co., Inc.	Antagonists of pcsk9
CN101679527A (zh)	2007-04-13	2010-03-24	诺瓦提斯公司	用于调节前蛋白转化酶枯草杆菌蛋白酶/kexin9型(pcsk9)的分子和方法
JOP20080381B1 (ar)	2007-08-23	2023-03-28	Amgen Inc	بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
EP2205639B1 (en)	2007-10-26	2015-12-23	Merck Sharp & Dohme Corp.	Anti-pcsk9 and methods for treating lipid and cholesterol disorders
AR070315A1 (es)	2008-02-07	2010-03-31	Merck & Co Inc	Anticuerpos 1b20 antagonistas de pcsk9
AR070316A1 (es)	2008-02-07	2010-03-31	Merck & Co Inc	Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
US9994923B2 (en)	2008-04-23	2018-06-12	Amgen Inc.	Neutralizing proprotein convertase subtilisin kexin type 9 (PCSK9) variants and uses thereof
TWI516501B (zh) *	2008-09-12	2016-01-11	禮納特神經系統科學公司	Ｐｃｓｋ９拮抗劑類
JO3672B1 (ar) *	2008-12-15	2020-08-27	Regeneron Pharma	أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
CN102596249A (zh) *	2009-10-30	2012-07-18	默沙东公司	Ax1和ax189 pcsk9拮抗剂和变体
AR079336A1 (es) *	2009-12-11	2012-01-18	Irm Llc	Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
SG183867A1 (en) *	2010-03-11	2012-10-30	Rinat Neuroscience Corp	ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING

2012
- 2012-08-29 AR ARP120103190A patent/AR087715A1/es unknown
- 2012-08-31 TW TW101131954A patent/TWI586687B/zh not_active IP Right Cessation
- 2012-09-12 PH PH1/2014/500576A patent/PH12014500576A1/en unknown
- 2012-09-12 JP JP2014530744A patent/JP6013487B2/ja not_active Expired - Fee Related
- 2012-09-12 MX MX2014003175A patent/MX347475B/es active IP Right Grant
- 2012-09-12 US US13/611,196 patent/US8530414B2/en not_active Expired - Fee Related
- 2012-09-12 MY MYPI2014700618A patent/MY168961A/en unknown
- 2012-09-12 EP EP12761863.5A patent/EP2756003A1/en not_active Withdrawn
- 2012-09-12 WO PCT/US2012/054737 patent/WO2013039958A1/en not_active Ceased
- 2012-09-12 CN CN201280044580.3A patent/CN103781802B/zh not_active Expired - Fee Related
- 2012-09-12 KR KR1020147006577A patent/KR101607783B1/ko not_active Expired - Fee Related
- 2012-09-12 UA UAA201401793A patent/UA114604C2/uk unknown
- 2012-09-12 CA CA2845706A patent/CA2845706C/en not_active Expired - Fee Related
- 2012-09-12 AP AP2014007499A patent/AP2014007499A0/xx unknown
- 2012-09-12 BR BR112014005799A patent/BR112014005799A2/pt active Search and Examination
- 2012-09-12 EA EA201490470A patent/EA024430B1/ru not_active IP Right Cessation
- 2012-09-12 PE PE2014000352A patent/PE20141147A1/es not_active Application Discontinuation
- 2012-09-12 AU AU2012308786A patent/AU2012308786B2/en not_active Ceased
- 2012-09-12 SG SG2014014187A patent/SG2014014187A/en unknown
2014
- 2014-02-19 ZA ZA2014/01267A patent/ZA201401267B/en unknown
- 2014-02-24 CR CR20140087A patent/CR20140087A/es unknown
- 2014-02-26 DO DO2014000041A patent/DOP2014000041A/es unknown
- 2014-03-03 IL IL231282A patent/IL231282A0/en unknown
- 2014-03-06 TN TNP2014000094A patent/TN2014000094A1/en unknown
- 2014-03-11 MA MA36818A patent/MA35433B1/fr unknown
- 2014-03-12 CL CL2014000590A patent/CL2014000590A1/es unknown
- 2014-03-13 EC ECSP14013242 patent/ECSP14013242A/es unknown
- 2014-03-13 GT GT201400049A patent/GT201400049A/es unknown
- 2014-03-14 CO CO14055604A patent/CO6910164A2/es active IP Right Grant

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11904017B2 (en)	2015-08-18	2024-02-20	Regeneron Pharmaceuticals, Inc.	Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab

Also Published As

Publication number	Publication date
ZA201401267B (en)	2015-11-25
AU2012308786B2 (en)	2016-12-15
PH12014500576A1 (en)	2014-04-28
CN103781802A (zh)	2014-05-07
NZ622393A (en)	2015-11-27
KR101607783B1 (ko)	2016-03-30
MA35433B1 (fr)	2014-09-01
US8530414B2 (en)	2013-09-10
IL231282A0 (en)	2014-04-30
EA024430B1 (ru)	2016-09-30
AR087715A1 (es)	2014-04-09
JP2014530188A (ja)	2014-11-17
US20130071405A1 (en)	2013-03-21
CA2845706C (en)	2016-03-22
SG2014014187A (en)	2014-05-29
DOP2014000041A (es)	2014-06-30
CA2845706A1 (en)	2013-03-21
PE20141147A1 (es)	2014-09-22
MX347475B (es)	2017-04-27
GT201400049A (es)	2015-05-28
MY168961A (en)	2019-01-28
AP2014007499A0 (en)	2014-03-31
MX2014003175A (es)	2015-03-05
TWI586687B (zh)	2017-06-11
BR112014005799A2 (pt)	2017-03-28
TN2014000094A1 (en)	2015-07-01
ECSP14013242A (es)	2014-07-31
TW201323444A (zh)	2013-06-16
UA114604C2 (uk)	2017-07-10
EA201490470A1 (ru)	2014-06-30
EP2756003A1 (en)	2014-07-23
WO2013039958A1 (en)	2013-03-21
AU2012308786A1 (en)	2014-02-27
CO6910164A2 (es)	2014-03-31
KR20140044939A (ko)	2014-04-15
JP6013487B2 (ja)	2016-10-25
CR20140087A (es)	2014-05-02
CN103781802B (zh)	2016-08-24

Similar Documents

Publication	Publication Date	Title
CL2014000590A1 (es)	2014-10-17	Anticuerpo o fragmento de union a antigeno del mismo que se une a pcsk9 humana; composicion farmaceutica que lo comprende; y su uso para tratar hiperlipidemia o hipercolesterolemia.
CL2014002750A1 (es)	2015-04-06	Anticuerpo aislado o fragmento que se enlaza a un estado inactiva de un receptor her; composición farmacéutica que lo comprende; uso del anticuerpo para tratar cancer
CL2013000843A1 (es)	2014-03-07	Anticuerpo aislado o fragmento de union a antigeno del mismo que se une especificamente a cd48 humano y bloquea la interaccion entre cd48 humano y un receptor de cd48; composicion farmaceutica que lo comprende; y su uso.
CL2013000390A1 (es)	2014-03-21	Anticuerpo monoclonal que se une al peptido beta amiloide n3pglu o fragmento de union a antigeno del mismo; composicion farmaceutica que lo comprende; y su uso para tratar la enfermedad de alzheimer.
GT201700102A (es)	2018-11-27	Conjugados de anticuerpo-fármaco
CL2011002482A1 (es)	2012-03-30	Anticuerpo biespecificos que se une especificamente a las proteinas erbb-3 humana y c-met humana; acido nucleico que lo codifica; composicion farmaceutica que lo comprende; y su uso para tratar cancer
CL2012001304A1 (es)	2012-08-03	Anticuerpo o fragmento de enlace a antígeno del mismo que se une al péptido humano c5a del sistema del complemento; composición farmacéutica que lo comprende; y su uso para el tratamiento de enfermedades inflamatorias agudas.
CL2014000758A1 (es)	2014-08-22	Anticuerpo aislado o fragmento del mismo que se une especificamente a erbb3; composicion farmaceutica que lo comprende; y su uso para inhibir el crecimiento tumoral.
CL2013002298A1 (es)	2014-08-08	Uso de una proteina de union con un dominio variable dual de inmunoglobulina (dvd-ig) que se une a il-1 alfa e il-1 beta para preparar un medicamento util para el tratamiento de la osteoartritis
BR112013013781A2 (pt)	2016-09-13	anticorpos humanizados para liv-1 e uso dos mesmos para tratar câncer
BR112015022123A8 (pt)	2018-05-22	Anticorpos, fragmentos de ligação ao antígeno dos mesmos que se ligam especificamente à hepcidina ou um peptídeo de hepcidina, uso, meio contentor e kit
CL2013003043A1 (es)	2014-06-20	Anticuerpos de un único dominio variable dab que se unen a cd40 humano; ácido nucleico que codifica dicho anticuerpo; vector y célula huésped que lo comprenden; composición farmacéutica; uso de dichos anticuerpos para tratar enfermedad inmune.
ECSP14028523A (es)	2015-09-30	Moléculas de anticuerpo anti-gcc y uso de las mismas
CL2011002306A1 (es)	2012-01-13	Anticuerpo o un fragmento de union a antigeno del mismo que se une especificamente a la integrina heterodimero alfa4beta7; y composicion que lo comprende.
CL2011002304A1 (es)	2012-04-09	Anticuerpo multiespecifico que comprende un dominio de union al antigeno que se une a egfr y a her3; acido nucleico que lo codifica; celula huesped; metodo de produccion; inmunoconjugado; formulacion farmaceutica que comprende el anticuerpo; y su uso para tratar el cancer.
CR20140585A (es)	2015-03-06	Proteinas de union a antigeno st2
CL2008001742A1 (es)	2008-11-21	Anticuerpo monoclonal que reconoce un epitope conformacional y se une a peptidos amiloides solubles polimericos y peptidos amiloides oligomericos; polinucleotido que lo codifica; composicion que lo comprende; y su uso para tratar enfermedades asociados a proteinas amiloides.
CL2013002811A1 (es)	2014-02-28	Anticuerpo monoclonal aislado que se une a un epitopo del inhibidor de la ruta del factor tisular humano; molecula de acido nucleico que lo codifica; composicion farmaceutica que lo comprende; y su uso para tratar deficiencias o defectos geneticos o adquiridos en la coagulacion.
CL2013000369A1 (es)	2014-08-08	Anticuerpo que se une especificamente a la proteina de activacion fibroblastica (fap); polinucleotido que lo codifica; vector; celula huesped; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar cancer.
CL2012002433A1 (es)	2013-03-22	Anticuerpo aislado o fragmento inmunoreactivo del mismo que comprende un dominio variable que se une específicamente a un dominio extracelular del receptor b7-h3; ácido nucleico que lo codifica; hibridoma que lo secreta; reactivo de redireccionamiento de doble afinidad (dart) que lo comprende; composición farmacéutica que lo comprende; y su uso para tratar cáncer.
CL2015000028A1 (es)	2015-02-27	Inmunoconjugado que comprende un anticuerpo anti-cd79b unido a un agente citotóxico derivado de nemorrubicina; formulación farmacéutica que lo comprende; y uso para tratar cáncer cd79b positivo.
BR112015007672A2 (pt)	2017-08-08	anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
CR20120105A (es)	2012-06-22	Proteínas terapéuticas de unión a dll4
BR112014002608A2 (pt)	2018-02-20	anticorpo ou seu fragmento que possui reatividade imunológica com um polipeptídeo caprin-1, composição farmacêutica e combinação farmacêutica de tratamento e/ou prevenção de câncer, dna e método de tratamento e/ou prevenção de câncer
BR112014008382A2 (pt)	2017-04-11	anticorpo especificamente ligando a epítope no domínio sema do c-met